Cargando…

Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study

Being rich in polyunsaturated fatty acids, flaxseed (Linum usitatissimum L.) is thought to be able to decrease lipid levels and dampen inflammation. In this pilot study, we aimed to determine whether flaxseed supplementation could improve the profiles of lipids and inflammatory mediators in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanikowska, Dominika, Korybalska, Katarzyna, Mickiewicz, Agnieszka, Rutkowski, Rafał, Kuchta, Agnieszka, Sato, Maki, Kreft, Ewelina, Fijałkowski, Marcin, Gruchała, Marcin, Jankowski, Maciej, Bręborowicz, Andrzej, Witowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231079/
https://www.ncbi.nlm.nih.gov/pubmed/32325781
http://dx.doi.org/10.3390/nu12041137
_version_ 1783535107973316608
author Kanikowska, Dominika
Korybalska, Katarzyna
Mickiewicz, Agnieszka
Rutkowski, Rafał
Kuchta, Agnieszka
Sato, Maki
Kreft, Ewelina
Fijałkowski, Marcin
Gruchała, Marcin
Jankowski, Maciej
Bręborowicz, Andrzej
Witowski, Janusz
author_facet Kanikowska, Dominika
Korybalska, Katarzyna
Mickiewicz, Agnieszka
Rutkowski, Rafał
Kuchta, Agnieszka
Sato, Maki
Kreft, Ewelina
Fijałkowski, Marcin
Gruchała, Marcin
Jankowski, Maciej
Bręborowicz, Andrzej
Witowski, Janusz
author_sort Kanikowska, Dominika
collection PubMed
description Being rich in polyunsaturated fatty acids, flaxseed (Linum usitatissimum L.) is thought to be able to decrease lipid levels and dampen inflammation. In this pilot study, we aimed to determine whether flaxseed supplementation could improve the profiles of lipids and inflammatory mediators in patients with severe hyperlipidemia resistant to conventional lipid-lowering pharmacotherapy and requiring lipoprotein apheresis. To this end, six patients received, blindly—in addition to their normal lipoprotein apheresis regimen—a 10-week dietary supplementation with flaxseed (28 g/d) administered in biscuits. This was followed by a 10-week washed out-period and a 10-week supplementation phase with whole wheat placebo. Blood samples were collected at the end of each phase, before the lipoprotein apheresis session. The primary endpoint was the lipid profile and the secondary endpoints were the concentrations of inflammatory mediators and tolerability. Flaxseed supplementation was well-tolerated and resulted in a consistent and significant decrease in total cholesterol and low-density lipoprotein (LDL) levels. The median (and range) percentage decrease was 11.5% (0–18.8) and 7.3% (4.4–26.6), for cholesterol (p = 0.015) and LDL-C (p = 0.003), respectively. On the other hand, there was no significant effect of flaxseed on lipoprotein(a) (Lp(a)), C-reactive protein (CRP), and interleukin 6 (IL-6) concentrations. These observations indicate that flaxseed can produce a cholesterol- and LDL-lowering effect in patients treated with lipoprotein apheresis. Thus, flaxseed supplementation may help to control cholesterol in this patient population. The flaxseed supplementation protocol applied may be of use for further adequately-powered studies to validate and extend our findings.
format Online
Article
Text
id pubmed-7231079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72310792020-05-22 Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study Kanikowska, Dominika Korybalska, Katarzyna Mickiewicz, Agnieszka Rutkowski, Rafał Kuchta, Agnieszka Sato, Maki Kreft, Ewelina Fijałkowski, Marcin Gruchała, Marcin Jankowski, Maciej Bręborowicz, Andrzej Witowski, Janusz Nutrients Article Being rich in polyunsaturated fatty acids, flaxseed (Linum usitatissimum L.) is thought to be able to decrease lipid levels and dampen inflammation. In this pilot study, we aimed to determine whether flaxseed supplementation could improve the profiles of lipids and inflammatory mediators in patients with severe hyperlipidemia resistant to conventional lipid-lowering pharmacotherapy and requiring lipoprotein apheresis. To this end, six patients received, blindly—in addition to their normal lipoprotein apheresis regimen—a 10-week dietary supplementation with flaxseed (28 g/d) administered in biscuits. This was followed by a 10-week washed out-period and a 10-week supplementation phase with whole wheat placebo. Blood samples were collected at the end of each phase, before the lipoprotein apheresis session. The primary endpoint was the lipid profile and the secondary endpoints were the concentrations of inflammatory mediators and tolerability. Flaxseed supplementation was well-tolerated and resulted in a consistent and significant decrease in total cholesterol and low-density lipoprotein (LDL) levels. The median (and range) percentage decrease was 11.5% (0–18.8) and 7.3% (4.4–26.6), for cholesterol (p = 0.015) and LDL-C (p = 0.003), respectively. On the other hand, there was no significant effect of flaxseed on lipoprotein(a) (Lp(a)), C-reactive protein (CRP), and interleukin 6 (IL-6) concentrations. These observations indicate that flaxseed can produce a cholesterol- and LDL-lowering effect in patients treated with lipoprotein apheresis. Thus, flaxseed supplementation may help to control cholesterol in this patient population. The flaxseed supplementation protocol applied may be of use for further adequately-powered studies to validate and extend our findings. MDPI 2020-04-18 /pmc/articles/PMC7231079/ /pubmed/32325781 http://dx.doi.org/10.3390/nu12041137 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kanikowska, Dominika
Korybalska, Katarzyna
Mickiewicz, Agnieszka
Rutkowski, Rafał
Kuchta, Agnieszka
Sato, Maki
Kreft, Ewelina
Fijałkowski, Marcin
Gruchała, Marcin
Jankowski, Maciej
Bręborowicz, Andrzej
Witowski, Janusz
Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title_full Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title_fullStr Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title_full_unstemmed Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title_short Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
title_sort flaxseed (linum usitatissimum l.) supplementation in patients undergoing lipoprotein apheresis for severe hyperlipidemia—a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231079/
https://www.ncbi.nlm.nih.gov/pubmed/32325781
http://dx.doi.org/10.3390/nu12041137
work_keys_str_mv AT kanikowskadominika flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT korybalskakatarzyna flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT mickiewiczagnieszka flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT rutkowskirafał flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT kuchtaagnieszka flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT satomaki flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT kreftewelina flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT fijałkowskimarcin flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT gruchałamarcin flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT jankowskimaciej flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT breborowiczandrzej flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy
AT witowskijanusz flaxseedlinumusitatissimumlsupplementationinpatientsundergoinglipoproteinapheresisforseverehyperlipidemiaapilotstudy